Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLONASDAQ:ARQTNASDAQ:GLPGNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$0.94-16.6%$1.55$0.87▼$3.78$206.11M0.63.36 million shs10.79 million shsARQTArcutis Biotherapeutics$13.79-0.2%$14.75$6.99▼$17.75$1.64B1.872.38 million shs818,172 shsGLPGGalapagos$26.54-1.1%$25.39$22.36▼$31.23$1.75B0.02228,855 shs519,075 shsTARSTarsus Pharmaceuticals$42.50+2.5%$48.21$20.08▼$57.28$1.79B0.94694,767 shs766,060 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-3.42%-11.72%-22.07%-20.98%-61.03%ARQTArcutis Biotherapeutics-3.96%-3.49%+9.77%+4.62%+72.97%GLPGGalapagos+7.06%+2.17%+11.79%+7.49%-5.73%TARSTarsus Pharmaceuticals-6.20%-10.74%-10.70%-20.77%+8.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLOAllogene Therapeutics3.654 of 5 stars4.53.00.00.02.33.30.6ARQTArcutis Biotherapeutics2.7692 of 5 stars4.41.00.00.03.40.80.6GLPGGalapagos0.4899 of 5 stars0.83.00.00.03.30.00.6TARSTarsus Pharmaceuticals3.0568 of 5 stars4.50.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.90Moderate Buy$8.89843.22% UpsideARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8036.33% UpsideGLPGGalapagos 1.50Reduce$25.33-4.55% DownsideTARSTarsus Pharmaceuticals 3.00Buy$66.3356.08% UpsideCurrent Analyst Ratings BreakdownLatest ALLO, TARS, ARQT, and GLPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ALLOAllogene TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.005/14/2025ALLOAllogene TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/5/2025TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.005/2/2025TARSTarsus PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $84.004/9/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/3/2025ARQTArcutis BiotherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$22K9,368.53N/AN/A$3.04 per share0.31ARQTArcutis Biotherapeutics$212.82M7.72N/AN/A$0.94 per share14.67GLPGGalapagos$288.19M6.07N/AN/A$47.57 per share0.56TARSTarsus Pharmaceuticals$233.67M7.64N/AN/A$5.95 per share7.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$327.27M-$1.33N/AN/AN/AN/A-52.13%-41.29%N/AARQTArcutis Biotherapeutics-$262.14M-$1.04N/AN/AN/A-140.97%-119.11%-45.95%N/AGLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)TARSTarsus Pharmaceuticals-$135.89M-$2.73N/AN/AN/A-103.64%-55.86%-39.28%5/14/2025 (Estimated)Latest ALLO, TARS, ARQT, and GLPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TARSTarsus Pharmaceuticals-$0.75N/AN/AN/A$71.19 millionN/A5/12/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 million3/13/2025Q4 2024ALLOAllogene Therapeutics-$0.34-$0.28+$0.06-$0.28$0.01 millionN/A2/25/2025Q4 2024ARQTArcutis Biotherapeutics-$0.28-$0.09+$0.19-$0.09$60.52 million$71.36 million2/25/2025Q4 2024TARSTarsus Pharmaceuticals-$0.68-$0.60+$0.08-$0.60$58.80 million$66.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.359.35ARQTArcutis Biotherapeutics0.672.462.38GLPGGalapagosN/A9.979.81TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%ARQTArcutis BiotherapeuticsN/AGLPGGalapagos32.46%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%ARQTArcutis Biotherapeutics9.50%GLPGGalapagos2.91%TARSTarsus Pharmaceuticals8.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310218.71 million158.72 millionOptionableARQTArcutis Biotherapeutics150119.20 million105.93 millionOptionableGLPGGalapagos1,31065.90 million63.98 millionOptionableTARSTarsus Pharmaceuticals5042.01 million35.07 millionOptionableALLO, TARS, ARQT, and GLPG HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 14 at 10:45 AM | zacks.comIntegral Health Asset Management LLC Has $19.38 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 14 at 6:17 AM | marketbeat.comD. E. Shaw & Co. Inc. Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 14 at 5:05 AM | marketbeat.comEnsign Peak Advisors Inc Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 13 at 6:32 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Schonfeld Strategic Advisors LLCMay 13 at 4:17 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by The Manufacturers Life Insurance CompanyMay 13 at 4:16 AM | marketbeat.comTarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay OffMay 12 at 12:28 PM | seekingalpha.comTudor Investment Corp ET AL Takes $769,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 10, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 62,658 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 10, 2025 | marketbeat.comTarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comCaxton Associates LP Buys New Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 9, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 8, 2025 | globenewswire.comCutter Capital Management LP Invests $6.23 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 8, 2025 | marketbeat.comThe Goldman Sachs Group Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $51.00May 7, 2025 | marketbeat.comVoya Investment Management LLC Purchases 18,000 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 7, 2025 | marketbeat.comRaymond James Financial Inc. Acquires Shares of 19,999 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 7, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $51.00 at The Goldman Sachs GroupMay 7, 2025 | americanbankingnews.comFreestone Grove Partners LP Makes New $439,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 6, 2025 | marketbeat.com6 Analysts Assess Tarsus Pharmaceuticals: What You Need To KnowMay 5, 2025 | benzinga.comTarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to AnalystsMay 5, 2025 | insidermonkey.comUncovering Potential: Supernus Pharmaceuticals's Earnings PreviewMay 5, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitCellectis Charts Course for 2025 With Boost From AstraZeneca DealBy Jeffrey Neal Johnson | April 22, 2025View Cellectis Charts Course for 2025 With Boost From AstraZeneca DealIs Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?By Leo Miller | May 6, 2025View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?ALLO, TARS, ARQT, and GLPG Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$0.94 -0.19 (-16.60%) As of 01:33 PM EasternAllogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Arcutis Biotherapeutics NASDAQ:ARQT$13.79 -0.03 (-0.22%) As of 01:34 PM EasternArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Galapagos NASDAQ:GLPG$26.54 -0.30 (-1.12%) As of 01:34 PM EasternGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Tarsus Pharmaceuticals NASDAQ:TARS$42.50 +1.04 (+2.51%) As of 01:34 PM EasternTarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
